This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Silvia Taylor, Senior Vice President Of Investor Relations, Public Relations, And Corporate Communications (Photo: Financial Communications Inc.)

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that Silvia Taylor has joined the company as Senior Vice President of Investor Relations, Public Relations, and Corporate Communications, reporting to Cary J. Claiborne, Chief Financial Officer. She will lead Sucampo’s investor relations, public relations, media relations and internal communications efforts with responsibility to establish the corporate brand, and to enhance Sucampo’s presence among the investment audience and other stakeholder groups as well as in the different communities in which the company operates globally.
Silvia Taylor, Senior Vice President of Investor Relations, Public Relations, and Corporate Communic ...

Silvia Taylor, Senior Vice President of Investor Relations, Public Relations, and Corporate Communications (Photo: Financial Communications Inc.)

Ryuji Ueno, M.D., Ph.D., Ph.D., Chair of the Board, CEO and CSO, said, “Ms. Taylor brings extensive experience in large and mid-size public biopharmaceutical companies, and we look forward to her leadership in defining our corporate brand and overarching communications strategy among all of our corporate and product-related audiences. She will build upon the corporate awareness campaign we started earlier this month to increase awareness of Sucampo and our proprietary prostone technology. And, as a science-driven pharmaceutical company, we will benefit from her experience in launching and marketing prescription medicines as we increase patient and healthcare provider access to our flagship product AMITIZA ®, launch RESCULA ® in the United States later this year, and further develop our prostone-based pipeline to meet the needs of millions of patients around the globe.”

Silvia Taylor brings 20 years of marketing and communications experience to Sucampo, including five years in public and media relations and 13 years in biopharmaceutical brand marketing at MedImmune and Pfizer Inc. She has expertise in marketing, strategy, new product launches, social media, direct-to-consumer advertising, communications, and public health, and has held leadership roles for Viagra ®, Exubera ®, motavizumab ®, Synagis ® and FluMist ® as well as other pre-launch products. Ms. Taylor joins Sucampo from MedImmune where she held positions of increasing responsibility, among them Senior Director of Marketing, RSV Franchise and Senior Director of Marketing, Global Influenza Franchise. Prior to MedImmune, Ms. Taylor worked at Pfizer from 1999 to 2007, where she worked on Viagra ® and Exubera ® and in the company’s consumer marketing department on patient-directed communications. She is an expert in engaging various healthcare-related audiences using a variety of communications tools, from advertising to sales promotion to Facebook ®. Ms. Taylor’s work has won numerous marketing and pharmaceutical industry awards. She graduated from the University of Virginia with a B.A. in Foreign Affairs and from Columbia Business School where she earned an MBA in Marketing and Management.

About Sucampo Pharmaceuticals

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.22 -0.02%
FB $117.47 -0.29%
GOOG $703.87 0.35%
TSLA $209.85 -0.79%
YHOO $37.11 0.46%


Chart of I:DJI
DOW 17,645.89 -14.82 -0.08%
S&P 500 2,043.36 -7.27 -0.35%
NASDAQ 4,701.3810 -15.7130 -0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs